Novartis reported a challenging first quarter for 2026, with profits experiencing a significant downturn primarily due to the intensified impact of generic competition on key revenue-generating drugs. While the Swiss pharmaceutical giant grappled with these headwinds, its strategic investments, particularly the substantial acquisition of Avidity Biosciences, position it for a more robust future, underscoring the broader industry trend of bolstering pipelines amidst an accelerating patent cliff.
The company’s financial disclosures for the first quarter revealed a 12% drop in profits, totaling $4.9 billion, compared to the corresponding period in 2025. This decline was mirrored in net sales, which reached $13.1 billion, a marginal 1% decrease from the $13.2 billion recorded in Q1 2025. Novartis attributed this dip directly to "US generic erosion," stating that this factor "more than offset any growth drivers." This sentiment highlights a critical juncture for the pharmaceutical sector, where the loss of exclusivity for blockbuster medications is exerting considerable pressure on established revenue streams.
The impact of generics was most acutely felt by Entresto (sacubitril/valsartan), Novartis’s flagship heart failure medication. Entresto, which had achieved peak annual sales of $7.8 billion in 2025, saw its quarterly performance plummet by an alarming 42% year-over-year. This dramatic decline serves as a stark indicator of the speed and scale at which generic versions can erode market share and revenue. Beyond Entresto, other significant products like the blood disorder treatment Promacta (eltrombopag) and the blood cancer therapy Tasigna (nilotinib) also experienced setbacks as generic alternatives entered the market.
During an earnings call, Novartis’s Chief Financial Officer, Mukul Mehta, acknowledged the difficult environment. "H1 will be impacted by a tough previous year [baseline] following US generic entries," Mehta stated, foreshadowing continued pressure in the initial half of the year. The company’s financial projections reflect this cautious outlook. Novartis anticipates a low single-digit decline in Q2 sales and projects full-year net sales to grow in the low single-digit range. For core operating income, the company forecasts a high single to low double-digit decline in Q2, with full-year profits expected to decrease by low single digits.
Despite these overarching challenges, the report also highlighted pockets of strength within Novartis’s portfolio. Citi analysts pointed to the robust performance of priority brands, including the oncology drug Kisqali (ribociclib) and the autoimmune disease treatment Kesimpta (ofatumumab), which contributed positively to the quarter, even as earnings per share (EPS) saw a 15% drop. This dual narrative of significant patent-driven declines alongside the resilience of newer, strategically important therapies underscores the complex dynamics at play within the company’s business.
The Accelerating Patent Cliff and the Strategic Imperative of M&A
Novartis’s Q1 performance is emblematic of a broader industry-wide phenomenon: the looming patent cliff. This refers to the period when a significant number of high-revenue-generating drugs lose patent protection, leading to a sharp decline in sales as generic and biosimilar competition emerges. The pharmaceutical sector is currently navigating one of the most substantial patent cliffs in its history, prompting a wave of strategic activity, particularly in mergers and acquisitions (M&A).
A July 2025 report by GlobalData projected a dramatic reduction in the share of global drug sales protected by patents by 2030, falling to just 4% from 12% in 2022 and 6% in 2024. This impending shift has intensified the pressure on pharmaceutical companies to replenish their pipelines with innovative assets. The M&A landscape in 2025 reflected this urgency, with deal values significantly outperforming those of 2024.
Novartis itself was a major participant in this M&A surge. In a landmark move, the company acquired RNA specialist Avidity Biosciences for $12 billion. This acquisition, one of the largest deals in the biopharmaceutical sector in 2025, significantly bolstered Novartis’s pipeline by adding three late-stage medicines targeting neuromuscular diseases.
During the Q1 earnings call, Novartis CEO Vas Narasimhan emphasized the strategic significance of the Avidity acquisition, citing it as a key source of optimism. Several critical milestones for these acquired assets are anticipated within the current year. These include a submission to the U.S. Food and Drug Administration (FDA) for del-zota, a candidate for Duchenne muscular dystrophy (DMD), and the release of Phase III trial results for del-desiran, which is being investigated for myotonic dystrophy type 1 (DM1).
Narasimhan elaborated on the strategic rationale, stating, "We’re increasingly excited about the opportunity we’re seeing in the pipeline to address more forms of DMD as well as apply the technology of antibody oligonucleotide conjugates to our own internal pipeline. We think that was the right decision and everything that we’ve seen since completing the acquisition continues to confirm that." This indicates a belief that the antibody oligonucleotide conjugate technology itself holds broad potential beyond the immediate pipeline assets.
Novartis’s commitment to strategic growth through acquisition has continued into 2026. In March, the company agreed to acquire Synnovation Therapeutics, a developer of cancer therapies, in a deal valued at up to $3 billion. In the same month, Novartis also entered into an agreement to purchase Excellergy, a specialist in allergy treatments, for a potential consideration of up to $2 billion. These acquisitions demonstrate a focused strategy to expand its therapeutic reach in key areas and acquire promising early- and mid-stage assets.
Internal Innovation and Future Growth Drivers
While M&A plays a crucial role, Novartis is also investing heavily in its internal research and development capabilities to drive long-term growth. The company’s internal pipeline features several compounds poised to contribute significantly to its future revenue.
A prime example is remibrutinib, a drug already approved under the brand name Rhapsido for multiple sclerosis (MS). Beyond its initial indication, remibrutinib is undergoing further clinical trials for hidradenitis suppurativa (HS), a chronic and often painful inflammatory skin condition. According to projections from GlobalData, remibrutinib is forecast to generate approximately $2.6 billion in sales by 2031, considering all its current and potential future indications. This underscores the potential for internally developed assets to become significant revenue generators.
The second half of 2026 is also expected to be a pivotal period for Novartis, with several key milestones anticipated for its internal pipeline. Notably, readouts are expected for ianalumab, an IgG1 monoclonal antibody. Novartis acquired ianalumab as part of its $2.9 billion buyout of MorphoSys, highlighting the company’s strategy of acquiring promising assets from smaller biotechs. Novartis holds considerable optimism for ianalumab, believing it has blockbuster potential.
Graham Parry, an analyst at Citi, commented on Novartis’s outlook, stating, "We continue to see scope for Novartis to beat consensus [with its sales guidance] and flagging potential for 2H26 pipeline readouts to increase this further." This sentiment suggests that the market is anticipating positive developments from Novartis’s pipeline, which could help offset the ongoing impact of generic erosion.
Broader Industry Implications and the Path Forward
The financial performance of Novartis in Q1 2026 serves as a microcosm of the broader challenges and strategic responses within the pharmaceutical industry. The undeniable impact of generic erosion on established revenue streams necessitates a proactive approach to pipeline replenishment. The significant investment in M&A, exemplified by Novartis’s acquisition of Avidity Biosciences, reflects a clear industry consensus on the necessity of acquiring external innovation to navigate the patent cliff.
However, the success of these strategies hinges not only on the volume of deals but also on the quality and integration of acquired assets, as well as the continued strength of internal R&D. The dual approach of strategic acquisitions and robust internal development appears to be the prevailing model for sustained growth in the current pharmaceutical landscape.
The coming years will be critical for Novartis and its peers as they strive to translate pipeline potential into tangible revenue growth. The successful development and commercialization of assets like remibrutinib and ianalumab, alongside the integration of acquired technologies and therapies, will be key determinants of their long-term success. As the industry grapples with the ongoing patent cliff, the ability to innovate, adapt, and strategically invest will define which companies emerge stronger and more resilient in the evolving global healthcare market. The current financial pressures, while significant, are being met with a determined strategic pivot, aiming to secure a future built on a foundation of cutting-edge science and diversified revenue streams.
Leave a Reply